Investigating the Safety and Efficacy of the Treatment With the Selution Sirolimus Coated Balloon in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb Ischemia From Singapore

Inclusion Criteria: * Age of subject is \> 21 years old * Patient has Critical Limb Ischemia, presenting a score from 4 to 6 following Rutherford Classification * Patient is willing to comply with specified follow-up evaluations at the specified times * Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study. * Patient has a projected life expectancy of at least 12 months and has not suffered an MI within past 30 days * Prior to enrolment, the guidewire has crossed the target lesion. * De novo and post-PTA restenotic lesions located in the tibial arteries suitable for endovascular therapy * Target lesion is located within the native tibial artery * The length of the target lesion is \>100mm and considered as TASC C or D lesion according to the TASC II Classification * The target lesion has angiographic evidence of stenosis \>50% or occlusion, which has been passed with standard guidewire manipulation and predilated to \<30% residual stenosis using either POBA or high pressure POBA. No other adjunctive devices have been used to prepare the lesion (example - scoring balloons, rotablator, atherectomy device) * Target vessel diameter is \>1.5mm and \<4.5mm below the knee * Either one or two different tibial arteries may be treated. Lesions in the treated segment may be continuous or may have gaps present between stenoses and occlusions. * Any tibial vessel intervened on must have distal reconstitution above the ankle * Inflow iliac, SFA and popliteal lesions can be treated during the same procedure using standard angioplasty and/or approved devices. These inflow lesions must be treated first prior to consideration of treatment of the BTK lesions. The patient can be enrolled if the inflow lesions are treated with good angiographic results (must have \<30% residual stenosis and no evidence of embolization) * There is angiographic evidence of at least one-vessel-runoff through the ankle and into the foot, irrespective of whether or not outflow was re-established by means of previous endovascular intervention. Exclusion Criteria: * Patient refusing treatment * Patient is permanently wheel-chair bound or bedridden * Presence of a stent in the target lesion that was placed during a previous procedure * The intervention is being performed in preparation of a planned amputation * Untreated flow-limiting inflow lesions * Any previous surgery in the target vessels (including prior ipsilateral crural bypass) * Previous bypass surgery in the same limb * Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated * Perforation at the angioplasty site evidenced by extravasation of contrast medium. * Untreatable lesion located at the distal outflow arteries * Patients with uncorrectable bleeding disorders * Aneurysm located at the level of the SFA/popliteal artery * Non-artherosclerotic disease resulting in occlusion * Any condition which prevents patients from complying with the study protocol or if patient has a life expectancy of \< 1 year. * Major distal amputation (above the transmetatarsal) in the study limb or non-study limb * Septicemia or bacteremia * Patient has undrained pus or spreading wet gangrene in the foot that is not controlled at the time of revascularization procedure * Neurotrophic ulcer or heel pressure ulcer or ulcer potentially involving calcaneus (index limb) * Episode of thrombectomy, cutting balloon, lithotripsy, atherectomy or laser devices during procedure * Any patient considered to be hemodynamically unstable at onset of procedure * Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure * The patient is currently breast-feeding, pregnant or intends to become pregnant * Subject receiving immunosuppression therapy, or has known serious immunosuppression therapy, or has known serious immunosuppressive disease (e.g. human immunodeficiency virus), or has severe autoimmune disease that requires chronic immunosuppressive therapy. The patient should also not receive inhibitors of CYP3A (such as Itraconazole, Erythromycin) or inducer of CYP3A (such as Rifampin) within 90 days following procedure * Patient is participating in another research study of a device, medication, biologic, or other agent within 30 days which could in the opinion of the investigator affect the results of this study * Patients with lesion to be treated with residual stenosis after POBA of \>30%